Norwegian health authorities announced that vaccines produced by Johnson & Johnson and AstraZeneca laboratories would be administered to those who request them voluntarily due to adverse effects reported in several European countries.
According to the Daily Mail, the country’s Institute of Public Health recommended that neither be used routinely due to “serious side effects,” as both injections are linked to the risk of serious blood clots.
The scenario of people developing blood clots raised concerns in countries such as Denmark, which stopped administering AstraZeneca’s vaccine altogether, as did Norway on March 11 after four people out of eight reported with clots died.
Although the clots were detected mainly with the AstraZeneca vaccine, Johnson & Johnson use the same formula, so the authorities decided to include the recommendation not to administer it massively as a preventive measure.
Camilla Stoltenberg, director of the Norwegian Institute of Public Health, said it was clear that side effects from the AstraZeneca injection were also associated with the J&J injection.
“It is clear that the rare but serious side effects that we have seen with AstraZeneca also appear with the use of Janssen,” she said. “There is great uncertainty as to the prevalence, and whether it occurs more often in some groups, such as according to age and gender.”
She added: “Nobody has been able to assure us it is easy to detect this side effect early enough to treat or prevent it, or secure that mortality would be lower than the high mortality that we have seen so far—though it varies in different datasets.”
Why clots occur
Clots occur along with low levels of platelets; a condition called thrombocytopenia.
Experts don’t know why coronavirus vaccines can trigger blockages in very rare cases, but one explanation is that it may be due to an overreaction of the immune system.
That is, the immune system starts attacking its own platelets instead of the virus. The body begins to overproduce platelets to compensate for those destroyed by the immune system. This can trigger the formation of clots with the clumped platelets before levels drop and cause thrombocytopenia.
Cases are more frequent in young people
Cases of blood clots were reported mainly in young people, and that is why France suspended vaccination with AstraZeneca in people under 55 years of age, while Germany did so in people under 65 years of age and the United Kingdom recommends that all people under 40 years of age seek an alternative to the British vaccine.
Because young people with no pre-existing conditions can carry the CCP Virus, just the common flu, the risks—although downplayed by health agencies—outweigh the benefits.
It is estimated that one young person in 60,000 is at risk of blood clots from these vaccines in the UK. But in Norway, the ratio drops to one person in 20,000.
Despite the clear intention of the media and health authorities to downplay the risks of experimental vaccines against the CCP Virus, which with the help of censorship in social networks, alternative information is scarce, serious cases are periodically reported worldwide.
A Tennessee woman reported being temporarily paralyzed after receiving a dose of the Pfizer vaccine.
Ten days later, she was able to move her limbs.